{"id":2970,"date":"2023-10-19T01:39:30","date_gmt":"2023-10-19T01:39:30","guid":{"rendered":"https:\/\/infundpros.com\/investment\/ardelyx-wins-long-battle-for-fda-approval-of-kidney-disease-treatment\/"},"modified":"2023-10-19T01:39:31","modified_gmt":"2023-10-19T01:39:31","slug":"ardelyx-wins-long-battle-for-fda-approval-of-kidney-disease-treatment","status":"publish","type":"post","link":"https:\/\/infundpros.com\/?p=2970","title":{"rendered":"Ardelyx wins long battle for FDA approval of kidney-disease treatment\u00a0"},"content":{"rendered":"
\n

Ardelyx Inc.
\n ARDX,
\n +13.33%<\/bg-quote>
\n on Tuesday won its long fight for U.S. regulatory approval of a treatment designed to help patients with chronic kidney disease. <\/p>\n

The biopharma company said late Tuesday that the U.S. Food and Drug Administration approved tenapanor, marketed under the brand name Xphozah, for control of serum phosphorus in patients with chronic kidney disease on dialysis. A high level of phosphorus in the blood is often a sign of kidney damage and can lead to weak bones, joint pain, cardiovascular problems and other issues. \u00a0\u00a0\u00a0<\/p>\n

\n

The approval concludes an extraordinary comeback for Xphozah. Ardelyx\u2019s application for approval of the treatment was previously rejected by the FDA in July 2021, when the agency said the drug\u2019s effect was \u201csmall and of unclear clinical significance.\u201d To preserve cash, Ardelyx a few months later said it would cut its workforce by 65%, but it also pursued multiple appeals of the agency\u2019s decision. An FDA advisory committee voted last November that the benefits of Xphozah outweigh its risks. The agency late last year ultimately granted Ardelyx\u2019s appeal, and the company resubmitted its Xphozah application to the FDA in April.\u00a0<\/p>\n

More than 550,000 people in the U.S. have chronic kidney disease and are on maintenance dialysis. The vast majority of them have high phosphorus levels, also called hyperphosphatemia, according to Ardelyx.\u00a0<\/p>\n

High phosphorus levels \u201cmust be taken care of in these patients, and the current therapies are mostly insufficient in doing so,\u201d Ardelyx CEO Mike Raab told MarketWatch.\u00a0<\/p>\n

Chronic kidney disease patients with high phosphorus levels have traditionally been treated with phosphate binders that can soak up phosphorus from food during digestion, but that approach can require patients to swallow a large number of pills. The Xphozah treatment requires two pills a day, \u201ceach the size of a Tic Tac,\u201d Raab said.\u00a0<\/p>\n

The FDA approved Xphozah as add-on therapy in patients who can\u2019t tolerate or have an inadequate response to phosphate binders, Ardelyx said in a release. <\/p>\n

Xphozah, which will be Ardelyx\u2019s second U.S. product launch, should be available sometime in November, Raab said. <\/p>\n

Ardelyx will present updated data on Xphozah for hyperphosphatemia at an American Society of Nephrology meeting in early November, the company said in a release Monday.\u00a0<\/p>\n

Ardelyx shares jumped in late September after Japanese regulators approved tenapanor for hyperphosphatemia in adults with chronic kidney disease on dialysis.\u00a0<\/p>\n

Ardelyx shares fell 0.6% on Tuesday and have gained 21% in the year to date, while the S&P 500
\n SPX
\n has gained 13.9%.\u00a0<\/p>\n<\/p><\/div>\n<\/div>\n

Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Ardelyx Inc. ARDX, +13.33% on Tuesday won its long fight for U.S. regulatory approval of a treatment designed to help patients with…<\/p>\n","protected":false},"author":1,"featured_media":2971,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":{"0":"post-2970","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-investment"},"yoast_head":"\nArdelyx wins long battle for FDA approval of kidney-disease treatment\u00a0 | inFundPros<\/title>\n<meta name=\"description\" content=\"Ardelyx Inc. ARDX, +13.33% on Tuesday won its long fight for U.S. regulatory approval of a treatment designed to help patients with chronic kidney\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/infundpros.com\/?p=2970\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ardelyx wins long battle for FDA approval of kidney-disease treatment\u00a0 | inFundPros\" \/>\n<meta property=\"og:description\" content=\"Ardelyx Inc. ARDX, +13.33% on Tuesday won its long fight for U.S. regulatory approval of a treatment designed to help patients with chronic kidney\" \/>\n<meta property=\"og:url\" content=\"https:\/\/infundpros.com\/?p=2970\" \/>\n<meta property=\"og:site_name\" content=\"inFundPros\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-19T01:39:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-19T01:39:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/1697679570_social.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"640\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Press Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Press Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/infundpros.com\/?p=2970#article\",\"isPartOf\":{\"@id\":\"https:\/\/infundpros.com\/?p=2970\"},\"author\":{\"name\":\"Press Room\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff\"},\"headline\":\"Ardelyx wins long battle for FDA approval of kidney-disease treatment\u00a0\",\"datePublished\":\"2023-10-19T01:39:30+00:00\",\"dateModified\":\"2023-10-19T01:39:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/infundpros.com\/?p=2970\"},\"wordCount\":430,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/infundpros.com\/#organization\"},\"articleSection\":[\"Investment\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/infundpros.com\/?p=2970#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/infundpros.com\/?p=2970\",\"url\":\"https:\/\/infundpros.com\/?p=2970\",\"name\":\"Ardelyx wins long battle for FDA approval of kidney-disease treatment\u00a0 | inFundPros\",\"isPartOf\":{\"@id\":\"https:\/\/infundpros.com\/#website\"},\"datePublished\":\"2023-10-19T01:39:30+00:00\",\"dateModified\":\"2023-10-19T01:39:31+00:00\",\"description\":\"Ardelyx Inc. ARDX, +13.33% on Tuesday won its long fight for U.S. regulatory approval of a treatment designed to help patients with chronic kidney\",\"breadcrumb\":{\"@id\":\"https:\/\/infundpros.com\/?p=2970#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/infundpros.com\/?p=2970\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/infundpros.com\/?p=2970#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/infundpros.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ardelyx wins long battle for FDA approval of kidney-disease treatment\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/infundpros.com\/#website\",\"url\":\"https:\/\/infundpros.com\/\",\"name\":\"Fintech Advance\",\"description\":\"Latest Finance and Tech News and Updates\",\"publisher\":{\"@id\":\"https:\/\/infundpros.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/infundpros.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/infundpros.com\/#organization\",\"name\":\"Fintech Advance\",\"url\":\"https:\/\/infundpros.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png\",\"contentUrl\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png\",\"width\":409,\"height\":70,\"caption\":\"Fintech Advance\"},\"image\":{\"@id\":\"https:\/\/infundpros.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff\",\"name\":\"Press Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png\",\"contentUrl\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png\",\"caption\":\"Press Room\"},\"sameAs\":[\"https:\/\/infundpros.com\"],\"url\":\"https:\/\/infundpros.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ardelyx wins long battle for FDA approval of kidney-disease treatment\u00a0 | inFundPros","description":"Ardelyx Inc. ARDX, +13.33% on Tuesday won its long fight for U.S. regulatory approval of a treatment designed to help patients with chronic kidney","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/infundpros.com\/?p=2970","og_locale":"en_US","og_type":"article","og_title":"Ardelyx wins long battle for FDA approval of kidney-disease treatment\u00a0 | inFundPros","og_description":"Ardelyx Inc. ARDX, +13.33% on Tuesday won its long fight for U.S. regulatory approval of a treatment designed to help patients with chronic kidney","og_url":"https:\/\/infundpros.com\/?p=2970","og_site_name":"inFundPros","article_published_time":"2023-10-19T01:39:30+00:00","article_modified_time":"2023-10-19T01:39:31+00:00","og_image":[{"width":1280,"height":640,"url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/1697679570_social.jpeg","type":"image\/jpeg"}],"author":"Press Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Press Room","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/infundpros.com\/?p=2970#article","isPartOf":{"@id":"https:\/\/infundpros.com\/?p=2970"},"author":{"name":"Press Room","@id":"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff"},"headline":"Ardelyx wins long battle for FDA approval of kidney-disease treatment\u00a0","datePublished":"2023-10-19T01:39:30+00:00","dateModified":"2023-10-19T01:39:31+00:00","mainEntityOfPage":{"@id":"https:\/\/infundpros.com\/?p=2970"},"wordCount":430,"commentCount":0,"publisher":{"@id":"https:\/\/infundpros.com\/#organization"},"articleSection":["Investment"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/infundpros.com\/?p=2970#respond"]}]},{"@type":"WebPage","@id":"https:\/\/infundpros.com\/?p=2970","url":"https:\/\/infundpros.com\/?p=2970","name":"Ardelyx wins long battle for FDA approval of kidney-disease treatment\u00a0 | inFundPros","isPartOf":{"@id":"https:\/\/infundpros.com\/#website"},"datePublished":"2023-10-19T01:39:30+00:00","dateModified":"2023-10-19T01:39:31+00:00","description":"Ardelyx Inc. ARDX, +13.33% on Tuesday won its long fight for U.S. regulatory approval of a treatment designed to help patients with chronic kidney","breadcrumb":{"@id":"https:\/\/infundpros.com\/?p=2970#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/infundpros.com\/?p=2970"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/infundpros.com\/?p=2970#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/infundpros.com\/"},{"@type":"ListItem","position":2,"name":"Ardelyx wins long battle for FDA approval of kidney-disease treatment\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/infundpros.com\/#website","url":"https:\/\/infundpros.com\/","name":"Fintech Advance","description":"Latest Finance and Tech News and Updates","publisher":{"@id":"https:\/\/infundpros.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/infundpros.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/infundpros.com\/#organization","name":"Fintech Advance","url":"https:\/\/infundpros.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/infundpros.com\/#\/schema\/logo\/image\/","url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png","contentUrl":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png","width":409,"height":70,"caption":"Fintech Advance"},"image":{"@id":"https:\/\/infundpros.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff","name":"Press Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/infundpros.com\/#\/schema\/person\/image\/","url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png","contentUrl":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png","caption":"Press Room"},"sameAs":["https:\/\/infundpros.com"],"url":"https:\/\/infundpros.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts\/2970","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2970"}],"version-history":[{"count":1,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts\/2970\/revisions"}],"predecessor-version":[{"id":2972,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts\/2970\/revisions\/2972"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/media\/2971"}],"wp:attachment":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2970"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2970"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2970"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}